Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with Lantern anticipating IRB approval at two additional sites during the fourth quarter. This expansion into Taiwan marks a significant step in the company's efforts to develop a targeted therapy for patients with the EGFR exon 21 L858R mutation, a subset of non-small cell lung cancer that often develops resistance to standard treatments.
In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation. Part 2 of the trial will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This change could potentially deepen or prolong treatment responses, offering new hope for patients with limited options.
Preliminary data from the trial showed a median progression-free survival of 8.9 months among nine L858R patients who completed six cycles of LP-300, compared with 8.3 months among all 16 L858R patients evaluated. While these findings are preliminary, exploratory, and based on small patient numbers, they suggest a potential benefit for this specific mutation subgroup. The company's RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data, is designed to identify patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development. This AI-driven approach could streamline drug development and improve precision in oncology.
The implications of this announcement are noteworthy for the oncology community. If LP-300 continues to show promise in the L858R subgroup, it could provide a much-needed option for patients who have progressed on tyrosine kinase inhibitors. The expansion into Taiwan also highlights the global nature of oncology research and the importance of international collaboration in bringing new therapies to patients. For investors, the progress of the HARMONIC trial represents a key milestone for Lantern Pharma, as successful trial outcomes could enhance the company's pipeline and attract further interest. Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For more details on Lantern Pharma, visit their company profile. The full press release can be accessed at https://ibn.fm/CqeDR, and the latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. This news was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire and other services. For a full list of terms and disclaimers, please see https://www.BioMedWire.com/Disclaimer.
